MDG1 Stock Overview
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.93 |
| 52 Week High | €2.70 |
| 52 Week Low | €1.41 |
| Beta | 0.85 |
| 1 Month Change | -18.78% |
| 3 Month Change | 33.68% |
| 1 Year Change | 6.94% |
| 3 Year Change | -50.32% |
| 5 Year Change | -78.38% |
| Change since IPO | -83.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDG1 | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -3.3% | -3.1% | -0.04% |
| 1Y | 6.9% | -14.1% | 2.2% |
Return vs Industry: MDG1 exceeded the Austrian Biotechs industry which returned -14.1% over the past year.
Return vs Market: MDG1 exceeded the Austrian Market which returned 2.2% over the past year.
Price Volatility
| MDG1 volatility | |
|---|---|
| MDG1 Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.0% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: MDG1's share price has been volatile over the past 3 months.
Volatility Over Time: MDG1's weekly volatility has increased from 11% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 76 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
| MDG1 fundamental statistics | |
|---|---|
| Market cap | €47.16m |
| Earnings (TTM) | -€16.18m |
| Revenue (TTM) | €6.03m |
7.8x
P/S Ratio-2.9x
P/E RatioIs MDG1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDG1 income statement (TTM) | |
|---|---|
| Revenue | €6.03m |
| Cost of Revenue | €1.64m |
| Gross Profit | €4.39m |
| Other Expenses | €20.57m |
| Earnings | -€16.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 72.77% |
| Net Profit Margin | -268.10% |
| Debt/Equity Ratio | 0% |
How did MDG1 perform over the long term?
See historical performance and comparison